Dr. Anders on Sequencing Strategies in the Setting of HER2+ Brain Metastases
October 17th 2019Carey Anders, MD, medical director, Brain and Spine Metastasis Program, and medical oncologist, Duke Cancer Institute, discusses sequencing strategies in the setting of HER2-positive breast cancer with brain metastases.
Read More
Dr. Anders Discusses the Use of Neratinib/Capecitabine for HER2-Positive Brain Metastases
October 8th 2019Carey Anders, MD, director, Brain and Spine Metastasis Program, Duke Cancer Institute, discusses the use of neratinib (Nerlynx) and capecitabine in patients with HER2-positive breast cancer that has metastasized to the brain.
Read More
Dr. Anders on Abemaciclib in HR+ Breast Cancer With Brain Metastases
June 22nd 2019Carey Anders, MD, director, Brain and Spine Metastasis Program, Duke Cancer Institute, discussed the use of abemaciclib, a selective CDK4/6 inhibitor, in patients with hormone receptor–positive, HER2-negative metastatic brain cancer with brain metastases.
Read More
Dr. Anders on Systemic Agents for Patients With Breast Cancer and Brain Mets
November 15th 2016Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses systemic agents available and in development for patients with breast cancer who also have brain metastases.
Read More
Dr. Anders on Challenge of Brain Mets in Breast Cancer
October 20th 2016Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses why brain metastases is such a prominent issue in patients with breast cancer in an interview during the 2016 OncLive State of the Science Summit on Metastatic Breast Cancer.
Read More